Provided by Tiger Fintech (Singapore) Pte. Ltd.

Compass Therapeutics, Inc.

2.20
+0.04502.09%
Volume:119.88K
Turnover:261.19K
Market Cap:303.53M
PE:-5.48
High:2.23
Open:2.15
Low:2.14
Close:2.15
Loading ...

Thomas J. Schuetz, CEO of Compass Therapeutics Inc., Reports Acquisition of Common Shares

Reuters
·
28 May

Compass Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
10 May

Compass Therapeutics Inc. expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
09 May

Analysts Are Bullish on These Healthcare Stocks: Compass Therapeutics (CMPX), REPRO-MED Systems (KRMD)

TIPRANKS
·
08 May

Compass Therapeutics: Ended Q1 With $113 Mln in Cash and Marketable Securities, Expected to Provide Cash Runway Into Q1 2027

THOMSON REUTERS
·
08 May

Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Compass Therapeutics (CMPX)

TIPRANKS
·
29 Apr

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire
·
28 Apr

Compass Therapeutics Price Target Maintained With a $24.00/Share by HC Wainwright & Co.

Dow Jones
·
22 Apr

Compass Therapeutics’ Tovecimig Shows Promise in BTC Treatment, Supporting Buy Rating

TIPRANKS
·
21 Apr

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients With Biliary Tract Cancer

THOMSON REUTERS
·
21 Apr

Compass Therapeutics Inc. - Secondary Endpoint Results Expected in Q4

THOMSON REUTERS
·
21 Apr

Major Stock Sell-Off at Compass Therapeutics by Key Directors!

TIPRANKS
·
12 Apr

Insider Moves: Key Executives Snap Up Compass Therapeutics Stock

TIPRANKS
·
09 Apr

Compass Therapeutics Price Target Maintained With a $12.00/Share by Guggenheim

Dow Jones
·
02 Apr

Compass Therapeutics Raised to Outperform From Market Perform by Leerink Partners

Dow Jones
·
02 Apr

Compass Therapeutics (CMPX) Receives a Buy from Guggenheim

TIPRANKS
·
02 Apr

Compass Therapeutics And 2 More Compelling Penny Stocks

Simply Wall St.
·
02 Apr

Leerink Partners Upgrades Compass Therapeutics to Outperform From Market Perform, Adjusts PT to $6 From $4

MT Newswires Live
·
02 Apr

Compass Therapeutics upgraded to Outperform from Market Perform at Leerink

TIPRANKS
·
02 Apr

Positive Buy Rating for Tovecimig-Paclitaxel Combo Following Promising COMPANION-002 Trial Results

TIPRANKS
·
02 Apr